Punicalagin
(Synonyms: 安石榴甙) 目录号 : GN10047
Punicalagin是一种鞣花单宁，一种酚类化合物，具有抗氧化、抗炎和抗癌等作用。
Cas No.:65995-63-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Punicalagin is a ellagitannin, a phenolic compound with antioxidant, anti-inflammatory and anticancer effects[1, 2]. Punicalagin is a reversible and non-competitive 3-chymotrypsin-like protease (3CLpro) inhibitor that inhibits SARS-CoV-2 replication in vitro[3].
In vitro, PC-3, LNCaP, and BPH-1 cells were treated with Punicalagin (10, 50, 100µM) for 24h. Punicalagin inhibited the viability of PC-3 and LNCaP cells in a dose-dependent manner, but had no significant effect on the viability of BPH-1 cells. Punicalagin (100µM) increased the expression of enrichment factors in PC-3 and LNCaP cells[4]. Punicalagin (12.5-100μM) treatment of thyroid cancer cell line BCPAP cells for 24h-48h inhibited cell viability in a time- and dose-dependent manner and increased the number of autophagic vacuoles (AVO) in cells, but did not induce apoptosis[5].
In vivo, Punicalagin (50mg/kg) was intraperitoneally injected into mice with collagen-induced arthritis (CIA) for 14 days, which reduced the severity of arthritis and bone destruction in mice and decreased serum IL-6 and TNF-α levels[6]. Punicalagin (25, 50, 100mg/kg) was orally administered to pregnant rats with L-NAME-induced preeclampsia (PE) for 7 days, which significantly reduced diastolic blood pressure, systolic blood pressure and mean arterial pressure, restored angiogenesis balance, and enhanced placental antioxidant capacity[7].
References:
[1] Venusova E, Kolesarova A, Horky P, et al. Physiological and immune functions of punicalagin[J]. Nutrients, 2021, 13(7): 2150.
[2] Rozadi N, Oktavia S, Fauziah F. Pharmacological Activities of Punicalagin: A Review[J]. Journal of Drug Delivery and Therapeutics, 2022, 12(2): 148-155.
[3] Du R, Cooper L, Chen Z, et al. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro[J]. Antiviral research, 2021, 190: 105075.
[4] Adaramoye O, Erguen B, Nitzsche B, et al. Punicalagin, a polyphenol from pomegranate fruit, induces growth inhibition and apoptosis in human PC-3 and LNCaP cells[J]. Chemico-biological interactions, 2017, 274: 100-106.
[5] Cheng X, Gao Y, Yao X, et al. Punicalagin induces apoptosis-independent autophagic cell death in human papillary thyroid carcinoma BCPAP cells[J]. RSC advances, 2016, 6(72): 68485-68493.
[6] Huang M, Wu K, Zeng S, et al. Punicalagin inhibited inflammation and migration of fibroblast-like synoviocytes through NF-κB pathway in the experimental study of rheumatoid arthritis[J]. Journal of inflammation research, 2021: 1901-1913.
[7] Wang Y, Huang M, Yang X, et al. Supplementing punicalagin reduces oxidative stress markers and restores angiogenic balance in a rat model of pregnancy-induced hypertension[J]. The Korean journal of physiology & pharmacology, 2018, 22(4): 409-417.
Punicalagin是一种鞣花单宁，一种酚类化合物，具有抗氧化、抗炎和抗癌等作用[1, 2]。Punicalagin是一种可逆且非竞争性的3-糜蛋白酶样蛋白酶（3CLpro）抑制剂，在体外可抑制 SARS-CoV-2 复制[3]。
在体外，使用Punicalagin（10, 50, 100µM）处理PC-3、LNCaP、BPH-1细胞24h，Punicalagin以剂量依赖性方式抑制了PC-3和LNCaP细胞的活力，但对BPH-1细胞的活力无显著影响。Punicalagin（100µM）增加了PC-3和LNCaP细胞中富集因子的表达[4]。Punicalagin（12.5-100μM）处理甲状腺癌细胞系BCPAP 细胞24h-48h，以时间和剂量依赖性方式抑制了细胞活力，增加了细胞中自噬空泡（AVO）的数量，但不诱导细胞凋亡[5]。
在体内，Punicalagin（50mg/kg）通过腹腔注射治疗胶原诱导性关节炎（CIA）小鼠14天，减轻了小鼠的关节炎严重程度和骨质破坏程度，降低了血清IL-6和TNF-α水平[6]。Punicalagin（25, 50, 100mg/kg）通过口服治疗L-NAME诱发先兆子痫（PE）的妊娠大鼠7天，显著降低了舒张压、收缩压和平均动脉压，恢复了血管生成平衡，增强了胎盘抗氧化能力[7]。
| Cell experiment [1]: | |
Cell lines | PC-3, LNCaP, BPH-1 cells |
Preparation Method | PC-3, LNCaP and BPH-1 cells were cultured in a 96-well microtiter plate containing 0.1mL of RPMI growth media/well for 24h. Cells were incubated with Punicalagin dissolved in DMSO, and Punicalagin concentrations of 10, 50 and 100µM were used with incubation period of 24-96h. Cells were evaluated for their viability using the XTT assay. |
Reaction Conditions | 10, 50, 100µM; 24h |
Applications | Punicalagin concentration-dependently inhibited viability in PC-3 and LNCaP cells, while viability in BPH-1 cells was insignificantly affected. |
| Animal experiment [2]: | |
Animal models | DBA/1 mice |
Preparation Method | DBA/1 mice (male, 8–9 weeks) were intradermally injected at the tail base with 200mg of bovine type II collagen emulsified at a 1:1 ratio (vol/vol) in Freund's complete adjuvant (day 0), and then boosted 21 days later using bovine type II collagen emulsified at a 1:1 ratio in incomplete Freund's adjuvant (day 21). Mice were randomly treated daily by intraperitoneal injection of DMSO (n=8) or Punicalagin (50mg/kg/day, n=8) for 14 days, which was initiated on the second day of booster immunization (day 22). Set up a normal control group including 8 mice without any treatment. Hindlimb samples were collected and fixed in 10% formalin for 48h. After a series of dehydration, waxing, and embedding, the joints were cut into 5µm thick sections for subsequent analysis. |
Dosage form | 50mg/kg/day for 14 days; i.p. |
Applications | Punicalagin alleviated arthritis severity and bone destruction, and decreased serum IL-6 and TNF-α in collagen-induced arthritis (CIA) mice. |
References: | |
| Cas No. | 65995-63-3 | SDF | |
| 别名 | 安石榴甙 | ||
| Canonical SMILES | O=C1OC2=C(C3=C(C(C(C(OC[C@H]4OC5O)=O)=CC(O)=C6O)=C6O)C(O)=C2O)C(C1=C(C(C(O)=C7O)=C(C=C7O)C(O[C@H]4[C@@H]([C@H]5OC8=O)OC(C(C(C(C(O)=C9O)=C8C=C9O)=C%10O)=CC(O)=C%10O)=O)=O)C(O)=C%11O)=C%11OC3=O | ||
| 分子式 | C48H28O30 | 分子量 | 1084.72 |
| 溶解度 | ≥ 108.4mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9219 mL | 4.6095 mL | 9.219 mL |
| 5 mM | 0.1844 mL | 0.9219 mL | 1.8438 mL |
| 10 mM | 0.0922 mL | 0.4609 mL | 0.9219 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet